Chloramphenicol-incorporated poly lactide-co-glycolide (PLGA) nanoparticles: Formulation, characterization, technetium-99m labeling and biodistribution studies

Journal of Drug Targeting

Volumn 16, Issue 4, 2008, Pages 311-320

  Halder, Kamal Krishna ^a   Mandal, Bivash ^b   Debnath, Mita Chatterjee ^a   Bera, Hriday ^b   Ghosh, Lakshmi Kanto ^b   Gupta, Bijon Kumar ^b  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Biodistribution; Chloramphenicol; Chloramphenicol loaded PLGA nanoparticles; Polysorbate 80 coated; Radiolabeling; Technetium 99m

Indexed keywords

CHLORAMPHENICOL; NANOPARTICLE; PENTETIC ACID; POLYGLACTIN; POLYSORBATE 80; POLYVINYL ALCOHOL; SOLVENT; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CHELATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; EMULSION; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CHELATING AGENTS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHLORAMPHENICOL; DRUG STABILITY; ELECTROCHEMISTRY; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; LACTIC ACID; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PENTETIC ACID; POLYGLYCOLIC ACID; TECHNETIUM; TIN COMPOUNDS; TISSUE DISTRIBUTION;

EID: 43049125484     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860801899300     Document Type: Article

References (23)

1. Allemann, E., Gurny, R. and Leroux, JC (1998) Biodegradable nanoparticles of polylactic acid and polylactic-co-glycolic acid for parenteral administration. Pharmacologic dosage form: Disperse systems, 3, pp. 163-193. Marcel Dekker Inc, New York
2. Alyautidin, RN, Petrov, VE, Langer, K., Berthold, A., Kharkevich, DA and Kreuter, J. (1997) Delivery of loperamide across the blood brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res, 14, pp. 325-328.
3. Ambruosi, A., Yamamoto, H. and Kreuter, J. (2005) Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target, 13, pp. 535-542.
4. Ambruosi, A., Khalansky, AS, Yamamoto, H., Gelperina, SE, Begley, DJ and Kreuter, J. (2006) Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly (butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma bearing rats. J Drug Target, 14, pp. 97-105.
5. Brannon-Peppas, L. (1995) Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm, 116, pp. 1-9.
6. Dillen, K., Vandervoort, J., Mooter, GV and Ludwig, A. (2006) Evaluation of Ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticle. Int J Pharm, 314, pp. 72-82.
7. Gulyaev, AE, Gelperina, SE, Skidan, IN, Antropov, AS, Kivman, Gy and Kreutere, J. (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res, 16, pp. 1564-1569.
8. Hughes, GA (2005) Nanostructure mediated drug delivery. Nanomedicine, 1, pp. 22-30.
9. Jimenez, JJ, Arimura, GK, Abok-khalil, WH, Isildar, M. and Yunis, AA (1987) Chloramphenicol-induced bone marrow injury: Possible role of bacterial metabolites of chloramphenicol. Blood, 70, pp. 1180-1185.
10. Koziara, JM, Lockman, PR, Allen, DD and Mumper, RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Rel, 99, pp. 259-269.
11. Lockman, PR, Mumper, RJ, Khan, MA and Allen, DD (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28, pp. 1-12.
12. Mainardes, RM and Evangelista, RC (2005) PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm, 290, pp. 137-144.
13. McCarroll, CS and Vogel, HL (1988) Multiple brain abscesses treated with antibiotics. J Am Osteopath Assoc, 88, pp. 657-661.
14. Olivier, JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx, 2, pp. 108-119.
15. Reddy, HL, Sharma, RK and Murthy, RSR (2004) Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's lymphoma tumor. J Drug Target, 12, pp. 443-451.
16. Reddy, HL, Sharma, RK, Chuttani, K., Mishra, AK and Murthy, RSR (2004) Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterisation, radiolabeling and biodistribution studies. AAPS J, 6, pp. 1-10.
17. Reddy, HL, Sharma, RK, Chuttani, K., Mishra, AK and Murthy, RSR (2005) Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Rel, 105, pp. 185-198.
18. Soppimath, KS, Aminabhavi, TM, Kulkarni, AR and Rudzinski, WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel, 70, pp. 1-20.
19. Troster, SD, Muller, U. and Kreuter, J. (1990) Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm, 61, pp. 85-100.
20. Videira, MA, Botelho, MF, Santos, AC, Gouveia, LF, Limade, JJ and Almeida, A. (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target, 10, pp. 607-613.
21. Wali, S., Macfarlane, J., Weir, W., Cleland, P., Hassn-king, M., Writtle, H. and Greenwood, B. (1979) Single injection treatment of meningococcal meningitis. Long acting chloramphenicol. Trans R Soc Trop Med Hyg, 73, pp. 698-702.
22. Wissing, SA, Kayser, O. and Muller, RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56, pp. 1257-1272.
23. Yunis, AA, Miller, AM, Salem, Z., Corbett, MD and Arimura, GK (1980) Nitrosochloramphenicol; Possible mediator in chloramphenicol induced aplastic anemia. J Lab Clin Med, 96, pp. 36-41.